48.17

6.72% -3.47

After Hours: 51.00 2.83 +5.88%

Structure Therapeutics Inc ADR (GPCR)

Overview News Price History Option Chain Financials Why GPCR Down? Discussions Forecast

Structure Therapeutics Inc ADR stock is currently priced at $48.17, with a 24-hour trading volume of 1.35M. It has seen a -6.72% decreased in the last 24 hours and a +34.93% rose in the past month. The chart indicates a potential bearish trend, as the stock is below the $52.04 pivot point. If it approaches the $48.23 support level, significant changes may occur.

Previous Close:

$51.64

Open:

$52.14

24h Volume:

1.35M

Market Cap:

$2.75B

Revenue:

Net Income/Loss:

$-89.62M

P/E Ratio:

-22.43

EPS:

-2.1478

Net Cash Flow:

$-81.66M

1W Performance:

-9.23%

1M Performance:

+34.93%

6M Performance:

-17.78%

1Y Performance:

+55.64%

1D Range:

$46.60

$52.14

52W Range:

$25.57

$75.02

Structure Therapeutics Inc ADR Stock (GPCR) Company Profile

Name

Structure Therapeutics Inc ADR

Sector

Healthcare (1212)

Industry

Biotechnology (696)

Phone

628-229-9277

Address

611 Gateway Boulevard, Suite 223, South San Francisco

Employee

Twitter

Next Earnings Date

Latest SEC Filings

GPCR's Discussions on Twitter

Structure Therapeutics Inc ADR Stock (GPCR) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
May-21-24	Initiated	JP Morgan	Overweight
Apr-09-24	Initiated	Cantor Fitzgerald	Overweight
Oct-19-23	Initiated	JMP Securities	Mkt Outperform
Jul-27-23	Initiated	Piper Sandler	Overweight
May-25-23	Resumed	Jefferies	Buy
Feb-28-23	Initiated	BMO Capital Markets	Outperform
Feb-28-23	Initiated	Guggenheim	Buy
Feb-28-23	Initiated	Jefferies	Buy
Feb-28-23	Initiated	SVB Securities	Outperform

View All

Structure Therapeutics Inc ADR Stock (GPCR) Latest News

A significant driver of top-line growth: Structure Therapeutics Inc ADR (GPCR) – Sete News - SETE News

SETE News

Pfizer: Headwinds Dissipating, New Obesity Pipeline Update Coming Soon

Seeking Alpha

Structure therapeutics CEO sells $9.76m in company shares By Investing.com - Investing.com

Investing.com

GPCR’s Financial Health: Exploring Structure Therapeutics Inc ADR’s Debt-to-Equity Ratio of 1.79 - The InvestChronicle

The InvestChronicle

GPCR’s Financial Health: Exploring Structure Therapeutics Inc ADR’s Debt-to-Equity Ratio of 1.79 - The InvestChronicle

The InvestChronicle

Structure Therapeutics (GPCR) Rallying on Obesity Drug Data - Yahoo Finance

Yahoo Finance

Structure Therapeutics Inc ADR Stock (GPCR) Financials Data

Structure Therapeutics Inc ADR (GPCR) Net Income 2024

GPCR net income (TTM) was -$89.62 million for the quarter ending December 31, 2023, a -74.63% decrease year-over-year.

Structure Therapeutics Inc ADR (GPCR) Cash Flow 2024

GPCR recorded a free cash flow (TTM) of -$81.66 million for the quarter ending December 31, 2023, a -76.46% decrease year-over-year.

Structure Therapeutics Inc ADR (GPCR) Earnings per Share 2024

GPCR earnings per share (TTM) was -$2.46 for the quarter ending December 31, 2023, a -28.26% decline year-over-year.

Structure Therapeutics Inc., a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. Its lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity. The company is also developing oral small molecule therapeutics targeting other GPCRs for the treatment of pulmonary and cardiovascular diseases, including ANPA-0073, a biased agonist, targeting apelin receptor, a GPCR that has been implicated in idiopathic pulmonary fibrosis (IPF) and pulmonary arterial hypertension; and LTSE-2578, an investigational oral small molecule lysophosphatidic acid 1 receptor antagonist for the treatment of IPF. The company was formerly known as ShouTi Inc. Structure Therapeutics Inc. was founded in 2016 and is headquartered in South San Francisco, California.